Most supplement ingredient breakdowns do one of two things: either endorse every ingredient uncritically by citing the most favorable research available, or dismiss everything because clinical trials weren't run on the finished formula. Neither approach is useful. What follows is a verified label analysis — every dose confirmed against the Supplement Facts panel, every ingredient evaluated against peer-reviewed literature, and honest assessment of where the evidence is strong, where it is preliminary, and where it is mixed.
This is Article 3 in a five-article series. For context on what MemoPryl is and how it's positioned, see What Is MemoPryl. For the product review and overall assessment, see the MemoPryl review. For safety, interactions, and who should not use this product, see MemoPryl side effects and safety.
The Verified Label
The Supplement Facts panel from the MemoPryl label — serving size 2 capsules, 30 servings per container — lists the following per serving. These are the only ingredient claims this analysis treats as verified. Any claims that appear only in marketing copy, FAQ responses, or website text but not on the Supplement Facts panel are not used as the basis for any ingredient assessment.
Active ingredients per serving: Branched Chain Amino Acids 2:1:1 (L-Leucine, L-Isoleucine, L-Valine) — 540 mg; Bacopa Monnieri Extract — 200 mg; Rhodiola Rosea Extract (3% Salidroside) — 100 mg; L-Theanine — 100 mg; Panax Ginseng Extract — 90 mg. All five carry a † symbol indicating Daily Value Not Established — consistent with their status as herbal/amino ingredients not assigned a standard dietary reference intake.
No discrepancy was found between the Supplement Facts panel and the promotional ingredient list for MemoPryl. The label is clean on ingredient content.
Ingredient 1: Branched Chain Amino Acids 2:1:1 — 540 mg
BCAAs are the dominant ingredient in MemoPryl by a substantial margin — 540 mg versus the next closest ingredient at 200 mg. They are listed as L-Leucine, L-Isoleucine, and L-Valine at a 2:1:1 ratio, which is industry-standard.
The vast majority of BCAA research concerns athletic performance, muscle protein synthesis, and exercise recovery — not cognitive function. What is the scientific rationale for their inclusion in a nootropic? BCAAs compete with aromatic amino acids (including tryptophan and tyrosine — precursors to serotonin and dopamine) for transport across the blood-brain barrier via the large neutral amino acid (LNAA) transport system. When plasma BCAA levels rise, more BCAAs cross the barrier and fewer aromatic amino acids do — which can modulate neurotransmitter availability. This mechanism is pharmacologically real (Fernstrom, J Nutr, 2005), but whether it translates into measurable cognitive support at 540 mg in a supplement context has not been established in controlled human trials.
A 2025 systematic review (PMC12709625) found preliminary evidence that BCAA supplementation combined with exercise may support hippocampal plasticity and cognitive function in aging populations — but explicitly noted that this domain requires further investigation and that current conclusions are not definitive.
The complicating finding: a 2022 study (Alzheimer's Research and Therapy, PMC9658564) found elevated circulating BCAAs in individuals with Alzheimer's disease, and BCAA restriction in animal models of AD delayed cognitive decline and reduced pathology. This does not mean BCAAs at 540 mg cause harm in healthy adults — it means the research picture is genuinely mixed and context-dependent. For healthy adults without Alzheimer's risk factors, this finding is not a practical concern at this dose. For individuals with diagnosed cognitive decline or Alzheimer's disease, it is a clinically relevant signal worth discussing with their physician.
Honest assessment: BCAAs at 540 mg have a plausible neurotransmitter-modulating mechanism, preliminary cognitive aging evidence, and a very strong safety profile in healthy adults. The cognitive evidence is far less developed than the athletic performance evidence. Their inclusion as the dominant ingredient in a cognitive supplement is unconventional.
Ingredient 2: Bacopa Monnieri Extract — 200 mg
Bacopa Monnieri is the strongest ingredient in MemoPryl from an evidence standpoint. It has more randomized controlled trial evidence for cognitive outcomes than any other ingredient in this formula.
The clinical literature: a 2012 systematic review in the Journal of Alternative and Complementary Medicine (PMID 22747190) analyzed RCTs on Bacopa in adults without dementia and concluded there is meaningful evidence for improvement in memory free recall. This finding has been replicated in subsequent trials. A 2024 systematic review (PMC11047749) confirmed that Bacopa's active bacosides A and B contribute to anti-apoptotic and antioxidant effects, with 22 included clinical trials demonstrating improvements in cognitive function, memory retention, and attention across multiple test populations. A 2025 review of preclinical and clinical evidence (PMC12158153) found modest improvements in memory performance in some trials, with results inconsistent across tests — noting that standardization of extract type and study methodology remains a challenge.
The dose question: most RCTs generating positive memory outcomes used 300–450 mg of standardized Bacopa extract. MemoPryl contains 200 mg. This is a real limitation. The evidence for Bacopa at 200 mg specifically is thinner than the evidence at 300–450 mg. This does not mean 200 mg is inert — Bacopa appears to have dose-dependent effects, and some effects may be present at lower doses — but the specific dose in MemoPryl was not the dose used in the strongest trials.
Honest assessment: Bacopa Monnieri is a well-supported cognitive ingredient with the most robust evidence base in this formula. The 200 mg dose is below the most studied range. This is the formula's most credible ingredient at a lower-than-optimal dose.
Ingredient 3: Rhodiola Rosea Extract (3% Salidroside) — 100 mg
Rhodiola Rosea is an adaptogen — a plant that supports the body's physiological stress response. Its cognitive support mechanism is indirect: by reducing the physiological and psychological impact of stress and fatigue, it supports cognitive performance under load. This is a legitimately different mechanism from a direct nootropic like Bacopa.
The clinical evidence: A 2022 review in Molecules (PMC9228580) summarized clinical studies on Rhodiola in stress, fatigue, and burnout contexts and found encouraging evidence for improvements in cognitive function and mental performance, particularly under conditions of stress-induced fatigue. A 2020 meta-analysis found significant reductions in stress and fatigue symptoms within four weeks of supplementation. The cognitive benefits observed in Rhodiola trials are most pronounced in participants experiencing burnout, high occupational stress, or sleep deprivation — not in well-rested, low-stress populations.
The standardization to 3% Salidroside is a quality signal. Salidroside is one of Rhodiola's primary bioactive compounds. Extract standardization — specifying the percentage of a known bioactive — is more reliable than non-standardized herbal products.
The dose: 100 mg of standardized Rhodiola extract is a workable dose for mild adaptogenic effects. Clinical trials have used a wide range — from 50 mg to 600 mg — with outcomes varying by standardization and study population. 100 mg is not a minimal token dose for this ingredient.
Honest assessment: Rhodiola at 100 mg (3% Salidroside) is a reasonable inclusion for stress-related cognitive fatigue. It will have the least effect on individuals who are not experiencing meaningful stress load.
Ingredient 4: L-Theanine — 100 mg
L-Theanine is an amino acid found naturally in green tea. It promotes alpha brain wave activity — the neural pattern associated with relaxed, alert focus — without sedation. Its most studied application is in combination with caffeine, where it modulates caffeine's stimulant effects to produce calm, sustained attention without jitteriness.
MemoPryl contains no caffeine. This is the clinically important context: the L-Theanine/caffeine synergy — probably the most well-documented nootropic combination in the academic literature — is not present in this formula. Standalone L-Theanine at 100 mg has its own evidence base for relaxed alertness and reduced cognitive anxiety, but the combined-compound research is stronger.
100 mg of L-Theanine is an appropriate dose for standalone use. Most studies examining L-Theanine for relaxed focus used doses in the 100–200 mg range. The ingredient is well-placed here; the absence of caffeine as a synergistic partner simply means its effect profile in MemoPryl will differ from the L-Theanine/caffeine literature.
Honest assessment: L-Theanine at 100 mg is a clean, evidence-supported ingredient for calm focus. It works differently here than in caffeine-containing formulas. Realistic expectations should account for that.
Ingredient 5: Panax Ginseng Extract — 90 mg
Panax Ginseng is one of the most studied herbal compounds in the world, with a long history in traditional Chinese and Korean medicine. Its primary bioactives — ginsenosides — are associated with anti-inflammatory effects, energy metabolism support, and cognitive performance in multiple clinical contexts.
The cognitive evidence: Multiple RCTs have demonstrated that Panax Ginseng can improve attention, working memory, and cognitive accuracy. A 90-participant study showed significant improvements in visual memory tests after 6 months of supplementation. Ginseng appears to sustain mental performance during prolonged tasks — a benefit most relevant for individuals experiencing cognitive fatigue rather than seeking acute enhancement.
The dose: 90 mg is on the lower end of the ginseng research range, which typically spans 200–400 mg of standardized extract. The extraction standardization for MemoPryl's Ginseng is not specified on the label — only the weight is given. This limits precision in dose-response estimation. A higher-quality product would specify the ginsenoside percentage for this ingredient.
Honest assessment: Panax Ginseng is a well-researched adaptogen with genuine cognitive support evidence. The 90 mg dose with unspecified standardization is lower than the best-evidence dose range. It is a credible inclusion but not the formula's strongest card.
The Formula as a Whole: What the Label Math Says
MemoPryl's five-ingredient formula is transparent — no proprietary blend, each dose listed individually. That transparency enables this kind of analysis. What does the dose math show?
The strongest cognitive evidence belongs to Bacopa Monnieri, but it's at 200 mg — below the 300–450 mg range where the best memory trials were conducted. Rhodiola and L-Theanine are at reasonable doses for mild adaptogenic and calm-focus effects respectively. Panax Ginseng is at a low dose with unspecified standardization. BCAAs dominate by weight and bring a plausible neurotransmitter-modulating mechanism with an unusual and genuinely mixed cognitive evidence profile.
No fabricated clinical trial on the finished MemoPryl formula has been cited here, because none exists. The analysis above reflects what is known about the individual ingredients at similar doses in peer-reviewed literature — which is the appropriate methodological standard for supplement ingredient evaluation.
For comparison with how this formula stacks up against alternatives, see our MemoPryl vs. Mind Lab Pro comparison. For the full product review, see the MemoPryl review. For safety and interaction information, see MemoPryl side effects and safety. For context on how other cognitive support supplements in this category are formulated, see our reviews of Mind Lab Pro and Noocube.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This content is for educational and informational purposes only.